← back to search

David M. Engelthaler

National Center for Emerging and Zoonotic Infectious Diseases · US
Area of research
Epidemiology · Infectious Diseases
Research interest
Research interests include Fungal Infections and Studies, Tuberculosis Research and Epidemiology, Mycobacterium research and diagnosis, and Plant Pathogens and Fungal Diseases.
h-index
54
citations
10,290
works
206
NIH funding
primary concept
email

Recent publications

Xpert MTB/RIF Ultra-resistant and MTBDR<i>plus-</i>susceptible rifampicin results in people with tuberculosis: utility of FluoroType MTBDR and deep sequencing.
2025cited by 2position: contributordoi
Distribution and transmission of M. tuberculosis in a high-HIV prevalence city in Malawi: A genomic and spatial analysis.
2025cited by 1position: middledoi
Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis.
2025cited by 1position: contributordoi
Unpacking bedaquiline hetero-resistance: the importance of intermediate profiles for phenotypic drug-susceptibility testing
2025cited by 0position: middledoi
The Hidden Epidemic of Isoniazid-Resistant Tuberculosis in South Africa
Annals of the American Thoracic Society 2024cited by 10position: middledoi
<i>In vitro</i> small molecule screening to inform novel candidates for use in fluconazole combination therapy <i>in vivo</i> against <i>Coccidioides</i>.
2024cited by 3position: middledoi
Investigation of SARS-CoV-2 Infection among Companion Animals in Households with Confirmed Human COVID-19 Cases.
2024cited by 2position: contributordoi
Lyssa excreta: Defining parameters for fecal samples as a rabies virus surveillance method.
2024cited by 2position: contributordoi
Distribution and transmission of <i>M. tuberculosis</i> in a high-HIV prevalence city in Malawi: a genomic and spatial analysis
2024cited by 1position: middledoi
Discovery and Repurposing of Pharmaceutical Agents as Antifungals: <i>In vivo</i> activity against <i>Coccidioides</i>
2024cited by 0position: middledoi
Xpert MTB/RIF Ultra resistant and MTBDR <i>plus</i> susceptible rifampicin results in people with tuberculosis: utility of FluoroType MTBDR and deep sequencing
2024cited by 0position: middledoi
Was &lt;i&gt;Coccidioides&lt;/i&gt; a Pre-Columbian Hitchhiker to Southcentral Washington?
2023cited by 4position: contributordoi
Unique Genomic Epidemiology of COVID-19 in the White Mountain Apache Tribe, April to August 2020, Arizona.
2023cited by 1position: contributordoi
Phylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis
PLOS Medicine 2022cited by 49position: middledoi
Comparative Performance of Genomic Methods for the Detection of Pyrazinamide Resistance and Heteroresistance in Mycobacterium tuberculosis.
2022cited by 12position: contributordoi
Modern lineages of <i>Mycobacterium tuberculosis</i> were recently introduced in western India and demonstrate increased transmissibility
2022cited by 2position: middledoi
Normalization of SARS-CoV-2 viral load via RT-qPCR provides higher-resolution data for comparison across time and between patients
Virus Research 2021cited by 9position: lastdoi
Genomic variant-identification methods may alter &lt;i&gt;Mycobacterium tuberculosis&lt;/i&gt; transmission inferences.
2020cited by 34position: middledoi
An Early Pandemic Analysis of SARS-CoV-2 Population Structure and Dynamics in Arizona.
2020cited by 29position: middledoi
Genomic analyses of <i>Staphylococcus aureus</i> clonal complex 45 isolates does not distinguish nasal carriage from bacteraemia.
2020cited by 8position: middledoi
Molecular Evaluation of Fluoroquinolone Resistance in Serial Mycobacterium tuberculosis Isolates from Individuals Diagnosed with Multidrug-Resistant Tuberculosis.
2020cited by 4position: contributordoi
Asymptomatic Employee Screening for SARS-CoV-2: Implementation of and Reactions to an Employer-Based Testing Program
2020cited by 0position: lastdoi
Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation
PLOS Medicine 2019cited by 64position: middledoi
On the Emergence of Cryptococcus gattii in the Pacific Northwest: Ballast Tanks, Tsunamis, and Black Swans.
2019cited by 28position: firstdoi
Minority <i>Mycobacterium tuberculosis</i> Genotypic Populations as an Indicator of Subsequent Phenotypic Resistance.
2019cited by 17position: firstdoi
Genomic Analyses of Acute Flaccid Myelitis Cases among a Cluster in Arizona Provide Further Evidence of Enterovirus D68 Role.
2019cited by 13position: lastdoi
Jet-Setting Koalas Spread Cryptococcus gattii VGII in Australia.
2019cited by 8position: contributordoi
Utility of Targeted, Amplicon-Based Deep Sequencing To Detect Resistance to First-Line Tuberculosis Drugs in Botswana.
2019cited by 4position: contributordoi
Bacterial Genome wide association studies (bGWAS) and transcriptomics identifies cryptic antimicrobial resistance mechanisms in <i>Acinetobacter baumannii</i>
2019cited by 2position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Paul Keim · Translational Genomics Research Institute4 papers (2019–2024)Darrin Lemmer · Flagstaff Medical Center4 papers (2019–2024)Megan Folkerts · Translational Genomics Research Institute3 papers (2024–2024) · 3 papers (2020–2024)Grant Theron · African Institute for Mathematical Sciences3 papers (2019–2025)Ted Cohen · Yale University3 papers (2020–2024)Robin M. Warren · South African Medical Research Council3 papers (2019–2024)Caroline Colijn · University of Calgary2 papers (2020–2022)Crystal M. Hepp · Translational Genomics Research Institute2 papers (2020–2023) · 2 papers (2024–2024)Nicolas A. Menzies · Management Sciences for Health2 papers (2022–2024) · 2 papers (2024–2024)Heather L. Mead · Translational Genomics Research Institute2 papers (2024–2024) · 2 papers (2020–2024)Christoffel Opperman · National Health Laboratory Service2 papers (2024–2025)Melanie H Chitwood · Ministério da Saúde2 papers (2022–2024)Jolene Bowers · Springer Nature2 papers (2020–2021)Elizabeth M. Streicher · South African Medical Research Council2 papers (2019–2024)Patrick G.T. Cudahy · Yale University2 papers (2022–2024)Bridget M. Barker · Northern Arizona University2 papers (2024–2024)